He discovered that microbubble technology greatly enhanced images of the heart and vascular system. His technology is quickly becoming part of the standard research protocol used in clinics and laboratories throughout the world. It is one of four inventions UneMed has patented and licensed for Dr. Porter. They hope to be the first to market use of the six types of group B CVBs, which are closely related to the poliovirus. CVBs cause meningitis, heart disease and pancreatitis.
Natural infection is the only way to build immunity, but once established, it is lifelong.
There are no vaccines available against these viruses. With the expected worldwide eradication of poliovirus to be completed within five years, however, work with poliovirus or clinical use of poliovirus vaccines is likely to be prohibited. Tracy and Chapman said with polio gone, CVBs are likely to become the human viruses of choice in researching their function and using them as an alternative vaccine delivery system. The breakthrough came nearly 18 years after Drs. Tracy and Chapman began their research.